~~<i id='3987C9C3D9'><strike id='3987C9C3D9'><tt id='3987C9C3D9'><pre id='3987C9C3D9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

Wikipedia

author：focus 2025-09-06 01:41:17 - browse：27396

Three sales executives, all of them women, have filed suit against Grail, a cancer diagnostics company, alleging that they were harassed, that the company failed to take corrective action, and that it retaliated by removing them from consideration for promotions.

The suits, which were filed earlier this week, are complicated by the fact that Grail was purchased by Illumina, the largest DNA sequencing firm, for $8 billion in 2021 — yet Illumina has left Grail to operate as a separate company. Illumina is named in the suit.

All three plaintiffs are being represented by the Vora Law Firm, based in Santa Monica, Calif.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Biden announces an advanced cancer research initiative

focus

explore

leisure time

focus

knowledge

Wikipedia

AdobeMorethan100,000doctorshave leftprivate practice andbecomeemployeesofhospitalsandothercorporatee

WSS

The mammogram wars are not over

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Why don't Americans have at

Ending health disparities requires full federal government, panel says

Resistance to opioid

Juul documents reveal insider tactics on political lobbying

entertainment

Wikipedia

focus

Sports medicine is finally prioritizing gender equality

STAT Boddities: What happens to the brain when we get scared?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Resistance to opioid

Tori Bowie and the unacceptable rates of Black maternal death

Why Eli Lilly’s earnings didn’t quite live up to the hype

United colonoscopy coverage change 'may cost lives,' doctors say

Marc Tessier

As demand for Covid shots wanes, Moderna seeks its next success

Why don't Americans have at

explore

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Resistance to opioid

Hospitals, health systems can help patients avoid medical debt

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

The mammogram wars are not over

leisure time

focus

knowledge

Wikipedia